Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
DNA Mismatch Repair | 3 | 2019 | 408 | 0.760 |
Why?
|
Microsatellite Instability | 3 | 2019 | 664 | 0.730 |
Why?
|
Mucin 5AC | 3 | 2023 | 102 | 0.730 |
Why?
|
DNA, Single-Stranded | 1 | 2019 | 347 | 0.680 |
Why?
|
Antibodies, Monoclonal | 13 | 2023 | 9584 | 0.670 |
Why?
|
Colorectal Neoplasms | 10 | 2022 | 6497 | 0.650 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 19 | 2023 | 11253 | 0.550 |
Why?
|
Interleukin-2 | 5 | 2017 | 1936 | 0.530 |
Why?
|
Salvage Therapy | 1 | 2019 | 1296 | 0.450 |
Why?
|
Pancreatic Neoplasms | 8 | 2023 | 4930 | 0.450 |
Why?
|
Immunotherapy | 6 | 2022 | 4057 | 0.430 |
Why?
|
Colonic Neoplasms | 4 | 2020 | 2535 | 0.400 |
Why?
|
Immunologic Factors | 1 | 2019 | 1578 | 0.390 |
Why?
|
Antineoplastic Agents | 6 | 2016 | 13714 | 0.280 |
Why?
|
Antigens, Neoplasm | 1 | 2013 | 2003 | 0.270 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5197 | 0.250 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2019 | 8877 | 0.250 |
Why?
|
Adenocarcinoma | 8 | 2023 | 6338 | 0.240 |
Why?
|
Melanoma | 4 | 2017 | 5194 | 0.230 |
Why?
|
Cancer Vaccines | 3 | 2015 | 1017 | 0.230 |
Why?
|
Neoplasm Metastasis | 7 | 2019 | 5112 | 0.210 |
Why?
|
Interleukin-12 | 1 | 2002 | 597 | 0.190 |
Why?
|
Maximum Tolerated Dose | 4 | 2016 | 914 | 0.180 |
Why?
|
Lectins, C-Type | 1 | 2002 | 617 | 0.180 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2023 | 1481 | 0.180 |
Why?
|
Carcinoma, Renal Cell | 3 | 2017 | 2910 | 0.170 |
Why?
|
Neoplasms | 6 | 2022 | 20172 | 0.160 |
Why?
|
Fluorouracil | 9 | 2011 | 1620 | 0.160 |
Why?
|
Combined Modality Therapy | 8 | 2022 | 8896 | 0.160 |
Why?
|
Deoxycytidine | 7 | 2011 | 837 | 0.160 |
Why?
|
Molecular Targeted Therapy | 3 | 2018 | 2878 | 0.150 |
Why?
|
Survival Rate | 8 | 2019 | 13202 | 0.150 |
Why?
|
Microsatellite Repeats | 1 | 2018 | 807 | 0.140 |
Why?
|
Photochemotherapy | 1 | 2022 | 833 | 0.140 |
Why?
|
Cell Adhesion Molecules | 1 | 2002 | 1673 | 0.140 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2020 | 3055 | 0.140 |
Why?
|
Neoplasm Staging | 10 | 2020 | 11126 | 0.130 |
Why?
|
Cytokines | 1 | 2009 | 7189 | 0.130 |
Why?
|
Protein Binding | 2 | 2019 | 9639 | 0.130 |
Why?
|
Aged | 29 | 2023 | 161488 | 0.120 |
Why?
|
GPI-Linked Proteins | 1 | 2015 | 453 | 0.120 |
Why?
|
Immunologic Memory | 1 | 2020 | 1391 | 0.120 |
Why?
|
Cyclophosphamide | 2 | 2019 | 2189 | 0.120 |
Why?
|
Rectal Neoplasms | 3 | 2007 | 1117 | 0.120 |
Why?
|
Listeria monocytogenes | 1 | 2015 | 260 | 0.120 |
Why?
|
Dendritic Cells | 2 | 2013 | 2726 | 0.120 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2013 | 315 | 0.110 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2013 | 315 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2018 | 11239 | 0.110 |
Why?
|
Female | 37 | 2023 | 375205 | 0.110 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2016 | 356 | 0.110 |
Why?
|
Protein Conformation | 1 | 2019 | 4057 | 0.110 |
Why?
|
Quinazolines | 2 | 2010 | 1420 | 0.110 |
Why?
|
Treatment Outcome | 13 | 2018 | 61932 | 0.110 |
Why?
|
Antigens, CD | 1 | 2002 | 4169 | 0.110 |
Why?
|
Male | 33 | 2023 | 349524 | 0.100 |
Why?
|
Leukemia | 1 | 2019 | 1496 | 0.100 |
Why?
|
Kidney Neoplasms | 2 | 2017 | 3970 | 0.100 |
Why?
|
Tumor Escape | 1 | 2013 | 328 | 0.100 |
Why?
|
Chromosomes | 1 | 2014 | 614 | 0.100 |
Why?
|
Skin Neoplasms | 1 | 2009 | 5266 | 0.100 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2019 | 1597 | 0.100 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2013 | 542 | 0.100 |
Why?
|
Tumor Microenvironment | 3 | 2022 | 2987 | 0.100 |
Why?
|
Proteoglycans | 1 | 2013 | 831 | 0.100 |
Why?
|
Melanoma, Experimental | 1 | 2013 | 560 | 0.100 |
Why?
|
Membrane Glycoproteins | 2 | 2016 | 3812 | 0.090 |
Why?
|
Middle Aged | 28 | 2023 | 213752 | 0.090 |
Why?
|
Follow-Up Studies | 7 | 2019 | 39038 | 0.090 |
Why?
|
Hematopoiesis | 1 | 2019 | 2015 | 0.090 |
Why?
|
Metabolic Clearance Rate | 1 | 2009 | 401 | 0.090 |
Why?
|
Humans | 40 | 2023 | 708843 | 0.090 |
Why?
|
Gene Expression Regulation | 3 | 2015 | 12447 | 0.090 |
Why?
|
Extremities | 1 | 2014 | 875 | 0.090 |
Why?
|
Half-Life | 1 | 2009 | 683 | 0.090 |
Why?
|
Ultrasonography | 1 | 2022 | 5918 | 0.090 |
Why?
|
Organoplatinum Compounds | 4 | 2011 | 431 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2536 | 0.080 |
Why?
|
Area Under Curve | 2 | 2009 | 1688 | 0.080 |
Why?
|
Esophageal Neoplasms | 2 | 2007 | 1449 | 0.080 |
Why?
|
Adult | 22 | 2023 | 211041 | 0.080 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2019 | 903 | 0.080 |
Why?
|
Cell Line, Tumor | 4 | 2022 | 16959 | 0.080 |
Why?
|
Duodenal Neoplasms | 1 | 2007 | 109 | 0.080 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4254 | 0.080 |
Why?
|
Tumor Burden | 1 | 2013 | 1906 | 0.080 |
Why?
|
Uracil | 2 | 2006 | 165 | 0.080 |
Why?
|
Sirolimus | 2 | 2012 | 1571 | 0.080 |
Why?
|
T-Lymphocyte Subsets | 1 | 2015 | 1924 | 0.070 |
Why?
|
Survival Analysis | 5 | 2020 | 10507 | 0.070 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2016 | 2981 | 0.070 |
Why?
|
Membrane Proteins | 1 | 2002 | 8072 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 3714 | 0.070 |
Why?
|
Biliary Tract Neoplasms | 1 | 2006 | 170 | 0.060 |
Why?
|
Recombinant Fusion Proteins | 1 | 2013 | 3878 | 0.060 |
Why?
|
Mice | 8 | 2022 | 80876 | 0.060 |
Why?
|
Prognosis | 4 | 2019 | 28919 | 0.060 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2006 | 654 | 0.060 |
Why?
|
Breast Neoplasms | 3 | 2022 | 19800 | 0.060 |
Why?
|
Triazenes | 1 | 2022 | 11 | 0.060 |
Why?
|
Models, Genetic | 1 | 2014 | 3539 | 0.060 |
Why?
|
Paclitaxel | 3 | 2023 | 1655 | 0.060 |
Why?
|
Disease-Free Survival | 5 | 2016 | 7026 | 0.060 |
Why?
|
Carrier Proteins | 1 | 2016 | 5141 | 0.060 |
Why?
|
Signal Transduction | 2 | 2022 | 23950 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 8024 | 0.050 |
Why?
|
Infusions, Intravenous | 2 | 2020 | 2303 | 0.050 |
Why?
|
CD40 Ligand | 1 | 2002 | 533 | 0.050 |
Why?
|
Neoadjuvant Therapy | 3 | 2007 | 2561 | 0.050 |
Why?
|
Interferon-gamma | 2 | 2015 | 3245 | 0.050 |
Why?
|
Animals | 9 | 2022 | 170486 | 0.050 |
Why?
|
Galectins | 1 | 2022 | 246 | 0.050 |
Why?
|
Lectins | 1 | 2002 | 557 | 0.050 |
Why?
|
Immunohistochemistry | 2 | 2015 | 11790 | 0.050 |
Why?
|
Recombinant Proteins | 2 | 2016 | 6850 | 0.050 |
Why?
|
Receptors, Chemokine | 1 | 2002 | 664 | 0.050 |
Why?
|
Immunoglobulins | 1 | 2002 | 917 | 0.050 |
Why?
|
Receptors, Somatomedin | 1 | 2018 | 60 | 0.040 |
Why?
|
Chemokine CCL5 | 1 | 2019 | 212 | 0.040 |
Why?
|
Heat-Shock Proteins | 1 | 2022 | 889 | 0.040 |
Why?
|
Photosensitizing Agents | 1 | 2022 | 614 | 0.040 |
Why?
|
Brain | 2 | 2015 | 24969 | 0.040 |
Why?
|
Aged, 80 and over | 8 | 2018 | 58184 | 0.040 |
Why?
|
Biopsy | 1 | 2009 | 6766 | 0.040 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2019 | 282 | 0.040 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2007 | 1829 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2019 | 71483 | 0.040 |
Why?
|
Cell Differentiation | 1 | 2014 | 11718 | 0.040 |
Why?
|
Enzyme Inhibitors | 2 | 2006 | 3936 | 0.040 |
Why?
|
Adenovirus E1 Proteins | 1 | 2015 | 7 | 0.040 |
Why?
|
Adenovirus E2 Proteins | 1 | 2015 | 11 | 0.040 |
Why?
|
Receptor, IGF Type 1 | 1 | 2018 | 399 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2012 | 4712 | 0.040 |
Why?
|
Ligands | 1 | 2022 | 3297 | 0.030 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2019 | 671 | 0.030 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2019 | 677 | 0.030 |
Why?
|
T-Lymphocytes | 1 | 2012 | 10362 | 0.030 |
Why?
|
Chemokine CCL22 | 1 | 2013 | 25 | 0.030 |
Why?
|
beta-Galactosidase | 1 | 2015 | 623 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2013 | 18375 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2007 | 3515 | 0.030 |
Why?
|
Stromal Cells | 1 | 2019 | 1361 | 0.030 |
Why?
|
Cell Lineage | 1 | 2002 | 2630 | 0.030 |
Why?
|
Animals, Newborn | 1 | 2019 | 2877 | 0.030 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2013 | 112 | 0.030 |
Why?
|
Liver Neoplasms | 1 | 2008 | 4044 | 0.030 |
Why?
|
Melphalan | 1 | 2014 | 385 | 0.030 |
Why?
|
Up-Regulation | 1 | 2002 | 4353 | 0.030 |
Why?
|
Receptors, Cell Surface | 1 | 2002 | 2913 | 0.030 |
Why?
|
Base Sequence | 2 | 2015 | 13352 | 0.030 |
Why?
|
Myoblasts | 1 | 2014 | 262 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2680 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2016 | 12183 | 0.030 |
Why?
|
Muscle Development | 1 | 2014 | 308 | 0.030 |
Why?
|
X Chromosome Inactivation | 1 | 2014 | 231 | 0.030 |
Why?
|
Mucositis | 1 | 2012 | 100 | 0.030 |
Why?
|
Hypokalemia | 1 | 2012 | 158 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2006 | 3876 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2015 | 1499 | 0.030 |
Why?
|
Hypocalcemia | 1 | 2012 | 197 | 0.030 |
Why?
|
Molecular Sequence Data | 2 | 2015 | 18748 | 0.030 |
Why?
|
Adenoviridae | 1 | 2015 | 1135 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2002 | 4466 | 0.020 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2015 | 641 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2015 | 1548 | 0.020 |
Why?
|
Immunization | 1 | 2015 | 1273 | 0.020 |
Why?
|
Radiotherapy Dosage | 2 | 2007 | 2927 | 0.020 |
Why?
|
Administration, Oral | 2 | 2011 | 3944 | 0.020 |
Why?
|
Time Factors | 2 | 2009 | 41038 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2012 | 10525 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 2768 | 0.020 |
Why?
|
Oligopeptides | 1 | 2015 | 1276 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 2 | 2010 | 2067 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2013 | 2165 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2015 | 2046 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2015 | 15274 | 0.020 |
Why?
|
Exanthema | 1 | 2012 | 456 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2015 | 20170 | 0.020 |
Why?
|
Young Adult | 4 | 2017 | 55940 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2015 | 9556 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2019 | 22989 | 0.020 |
Why?
|
Prodrugs | 1 | 2008 | 273 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2019 | 3447 | 0.020 |
Why?
|
Embryonic Stem Cells | 1 | 2014 | 1386 | 0.020 |
Why?
|
Down-Regulation | 1 | 2013 | 3093 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2013 | 1993 | 0.020 |
Why?
|
Camptothecin | 1 | 2008 | 555 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2014 | 2040 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2019 | 4861 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2011 | 1782 | 0.020 |
Why?
|
ras Proteins | 1 | 2011 | 1116 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3968 | 0.020 |
Why?
|
Hepatectomy | 1 | 2008 | 561 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2013 | 6684 | 0.020 |
Why?
|
Esophagectomy | 1 | 2007 | 458 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2012 | 5045 | 0.020 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2007 | 630 | 0.020 |
Why?
|
Carboplatin | 1 | 2006 | 797 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2015 | 4926 | 0.020 |
Why?
|
Piperidines | 1 | 2011 | 1582 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 1667 | 0.020 |
Why?
|
Chromatin | 1 | 2014 | 2693 | 0.010 |
Why?
|
Registries | 1 | 2017 | 7989 | 0.010 |
Why?
|
Cisplatin | 1 | 2007 | 1651 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2011 | 4883 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2011 | 2936 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 6293 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2007 | 3562 | 0.010 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2011 | 1922 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2013 | 9927 | 0.010 |
Why?
|
Fatigue | 1 | 2007 | 1450 | 0.010 |
Why?
|
Diarrhea | 1 | 2007 | 1354 | 0.010 |
Why?
|
Aging | 1 | 2019 | 8358 | 0.010 |
Why?
|
Pyridines | 1 | 2011 | 2862 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2007 | 2951 | 0.010 |
Why?
|
Drug Combinations | 1 | 2004 | 1925 | 0.010 |
Why?
|
Radiotherapy | 1 | 2006 | 1623 | 0.010 |
Why?
|
Genomics | 1 | 2014 | 5300 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2011 | 4677 | 0.010 |
Why?
|
Regression Analysis | 1 | 2007 | 6451 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13298 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2008 | 3490 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 19423 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2005 | 6530 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2010 | 5405 | 0.010 |
Why?
|
Transcription Factors | 1 | 2014 | 12005 | 0.010 |
Why?
|
Algorithms | 1 | 2014 | 13647 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2005 | 12292 | 0.010 |
Why?
|
Prospective Studies | 1 | 2014 | 50597 | 0.010 |
Why?
|
Cohort Studies | 1 | 2012 | 39292 | 0.010 |
Why?
|
Mutation | 1 | 2011 | 29262 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2008 | 20308 | 0.000 |
Why?
|
Risk Factors | 1 | 2005 | 69553 | 0.000 |
Why?
|
Concepts
(233)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(19)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_